Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 8/20 | 0.42 |
| ▸ | KDM1A | O60341 | 3/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 6/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | UBE2N | P61088 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6801364 | 1.00 | KLK7 (0.42) | KLK7KDM1AMAOAMAOBKCNH2 | |
| SCHEMBL6799779 | 0.94 | HTR6 (0.44) | KLK7KDM1AMAOAMAOBKCNH2 | |
| SCHEMBL6799995 | 0.94 | HTR6 (0.44) | KLK7KDM1AMAOAMAOBKCNH2 | |
| SCHEMBL6627879 | 0.94 | HTR6 (0.44) | KLK7KDM1AMAOAMAOBKCNH2 | |
| SCHEMBL6800623 | 0.94 | HTR6 (0.44) | KLK7KDM1AMAOAMAOBKCNH2 | |
| SCHEMBL6806305 | 0.91 | KLK7 (0.44) | KLK7KDM1AMAOAMAOBKCNH2 | |
| SCHEMBL6806308 | 0.91 | KLK7 (0.44) | KLK7KDM1AMAOAMAOBKCNH2 | |
| SCHEMBL6613796 | 0.88 | KDM1A (0.44) | KLK7KDM1AMAOAMAOBKCNH2 | |
| SCHEMBL6613791 | 0.88 | KDM1A (0.44) | KLK7KDM1AMAOAMAOBKCNH2 | |
| SCHEMBL6628213 | 0.86 | HTR6 (0.43) | KLK7KDM1AMAOAMAOBKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777437-B2 | ANTIDEPRESSANTS, ANXIOLYTIC AGENTS. SEXUAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-20040143003-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | MATTSON RONALD J (US) | 2004-07-22 | — | — | US | disclosed |
| US-20030073849-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143003-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | HTR1A, HTR1D, TPH1 | KLK7 2774/4885KDM1A 3085/4885MAOA 112/4885 |
| US-20030073849-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | HTR5A, HTR1A, HTR2C | KLK7 2523/4885KDM1A 3748/4885MAOA 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.